XOMA Royalty (XOMA) Cash from Restructuring (2016 - 2017)
XOMA Royalty (XOMA) reported Cash from Restructuring of -$314000.0 for Q4 2017, down 108.78% on a YoY basis from $3.6 million in Q4 2016, and up 45.49% sequentially from -$576000.0 in Q3 2017.
XOMA Royalty (XOMA) Cash from Restructuring (2016 - 2017) Analysis & Trends
XOMA Royalty (XOMA) has 2 years of Cash from Restructuring data on file, last reported at -$314000.0 in Q4 2017.
- For the quarter ending Q4 2017, Cash from Restructuring fell 108.78% year-over-year to -$314000.0; the trailing twelve-month figure through Dec 2017 stood at -$3.5 million (down 210.49% YoY), and the FY2017 full-year result was -$3.5 million, down 210.49% from the prior year.
- Cash from Restructuring grew to -$314000.0 in Q4 2017, from -$576000.0 in the prior quarter.
- In the past five years, Cash from Restructuring ranged from a high of $3.6 million in Q4 2016 to a low of -$1.8 million in Q1 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | -314,000.00 |
| Sep 30, 2017 | -576,000.00 |
| Jun 30, 2017 | -773,000.00 |
| Mar 31, 2017 | -1.80 Mn |
| Dec 31, 2016 | 3.58 Mn |
| Sep 30, 2016 | 1,000.00 |
| Jun 30, 2016 | -120,000.00 |
| Mar 31, 2016 | -321,000.00 |